DDInter657 DDInter1376
A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Epoprostenol {u} (Compound) resembles {v} (Compound) Dinoprost Tromethamine
Epoprostenol {u} (Compound) resembles {v} (Compound) Treprostinil
Epoprostenol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alprostadil
Epoprostenol {u} (Compound) binds {v} (Gene) P2RY12
Epoprostenol {u} (Compound) palliates {v} (Disease) systemic scleroderma
Epoprostenol {u} (Compound) is included by {v} (Pharmacologic Class) Vasodilation
Epoprostenol {u} (Compound) causes {v} (Side Effect) Hypoaesthesia
Epoprostenol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Epoprostenol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Digoxin
Epoprostenol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plicamycin
Epoprostenol (Compound) resembles Dinoprost Tromethamine (Compound)
Epoprostenol (Compound) resembles Treprostinil (Compound)
Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Alprostadil
Epoprostenol (Compound) binds P2RY12 (Gene)
Epoprostenol (Compound) palliates systemic scleroderma (Disease)
Epoprostenol (Compound) is included by Vasodilation (Pharmacologic Class)
Epoprostenol (Compound) causes Hypoaesthesia (Side Effect)
Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Capsicum
Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Digoxin
Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Plicamycin